Xilio Therapeutics Inc., a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced multiple upcoming presentations at the Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, scheduled for November 6-9, 2025, at the Gaylord National Convention Center in National Harbor, Maryland. The company will present new clinical data on vilastobart, a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, and efarindodekin alfa (XTX301), a tumor-activated IL-12. Additionally, preclinical data on Xilio's masked T cell engager programs will be showcased. Specific poster presentations include an analysis of ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable metastatic colorectal cancer, pharmacodynamic data from the first-in-human phase 1 study of XTX301 in advanced solid tumors, and data on masked T cell engagers designed for synthetic anti-tumor immunity with favorable tolerability. The results will be presented during the SITC Annual Meeting and have not yet been disclosed.